Get started
Author

Fabius Wiesmann

Observed name: Wiesmann, Fabius
ORCID: 0000-0003-1468-2076
Observed ORCID: 0000-0003-1468-2076
OpenAlex ID: A5057396435
In vivo CRISPR screens reveal the landscape of immune evasion pathways across cancer
2022 · Juan Dubrot, Peter P. Du, et al. · Nature Immunology · 219
SPECT Imaging of SST2-Expressing Tumors with 99mTc-Based Somatostatin Receptor Antagonists: The Role of Tetraamine, HYNIC, and Spacers
2021 · Raghuvir Haridas Gaonkar, Fabius Wiesmann, et al. · Pharmaceuticals · 10
PDF
Targeting mTORC1 Activity to Improve Efficacy of Radioligand Therapy in Cancer
2022 · Michal Grzmil, Fabius Wiesmann, et al. · Cancers · 7
PDF
CD4 memory T cells orchestrate therapy-responsive immune niches in colorectal cancer liver metastases
2025 · Maud Mayoux, Gioana Litscher, et al. · bioRxiv (Cold Spring Harbor Laboratory) · 2
The chromatin guardian ATRX is a strong prognostic biomarker in melanoma
2026 · Frei, Céline Arlette, Litchfield, Cassandra, et al. · Zurich Open Repository and Archive (University of Zurich)
The chromatin guardian ATRX is a strong prognostic biomarker in melanoma
2025 · Céline Arlette Frei, Cassandra Litchfield, et al. · Scientific Reports
PDF
The chromatin guardian ATRX is a strong prognostic biomarker in melanoma
2025 · Frei, Céline Arlette, Litchfield, Cassandra, et al. · Repository for Publications and Research Data (ETH Zurich)
RIPPLET: Mutation-Only Gene and Pathway Profiling for Precision Oncology
2025 · Fabius Wiesmann, Cassandra Litchfield, et al. · bioRxiv (Cold Spring Harbor Laboratory)
Abstract 3610: In vivo CRISPR screens reveal the landscape of immune evasion pathways across cancer
2022 · Juan Dubrot, Peter P. Du, et al. · Cancer Research
Works count: 9
Citation count: 238
H-index: 3
I10-index: 2
Year
Topic
Type